LLY vs NUWE
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Nuwellis, Inc. exhibits severe financial distress, highlighted by a critical Piotroski F-Score of 1/9 and a devastating 1-year price decline of 96.9%. While the company maintains a low debt-to-equity ratio, its profitability metrics are catastrophic, with a profit margin of -211.86% and an ROE of -382.55%. Revenue growth is stagnant at 4.4%, failing to offset massive operational losses. The technical trend is completely bearish (0/100), suggesting a lack of investor confidence and a high risk of further capital erosion.
Compare Another Pair
Related Comparisons
LLY vs NUWE: Head-to-Head Comparison
This page compares Eli Lilly and Company (LLY) and Nuwellis, Inc. (NUWE) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.